CALT Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -0.76%, SMA50 1.28%, SMA200 39.49%). The stock’s 14-day RSI is 50.49 (neutral), while the ATR of 1.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.98% below its high and over 162.3% above its low.

Calliditas Therapeutics AB (publ) generated EPS of -$1.69 over the past year. Five-year average earnings growth is -22.85%. The latest quarter delivered EPS of -$0.58. The next quarter is forecast at $0.15. Next year's EPS is expected at $254.98. Calliditas Therapeutics AB (publ) earnings surprise history is a mixed track record. The quarter that ended November 11, 2024, missed forecasts by 163.64%. The prior quarter beat by 23.08%. Over the last six quarters, Apple has recorded several small beats. These include 163.64% in November 07, 2023.

Calliditas Therapeutics AB (publ) has 27.02 million shares outstanding. The public float is 676.75 thousand shares, elevated short interest at 0.02% of float. This equals 3.49 thousand shares. The short ratio is 0.3 days.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) closed at $40.00 USD, losing -$0.04 (-0.10%) from the previous close of $40.04. The stock is currently mid-range between its 52-week high and low $15.25 and $43.00. With a market capitalization of about $2.15 billion, Calliditas Therapeutics AB (publ) is classified as a mid-cap and shows higher-than-market volatility (beta ~1.46). Key stats such as the average daily volume over the past year has been around 7.73 thousand shares, in line with its 52-week average. Headquartered in Stockholm, None, Calliditas Therapeutics AB (publ) operates in the Healthcare sector and the Biotechnology industry. Led by CEO Renee Aguiar-Lucander, the company employs approximately 222 people and listed since June 05, 2020. Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases.

Our AI price prediction model suggests that Calliditas Therapeutics AB (publ) stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.15%, with price expected at $39.94 by October 11, 2024, within a range of $39.41 to $40.43 3-Month Outlook: Projected fall of -37.6%, reaching $24.96 by December 19, 2024, with a range of $19.23 to $27.54. 1-Year Outlook: Projected gain of 19.88%, with price at $47.95 by September 19, 2025, within a range of $46.01 to $50.26.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) shares are up 55.38% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Calliditas Therapeutics AB (publ) trading at a premium to the broader market with a P/E of -21.52. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $43.75, suggesting 9.38% upside. Our AI forecast model points to short-term weakness (-0.15% over two weeks), a medium-term fall (-37.6% over three months), and a longer-term gain (19.88% over one year), with expected trading ranges indicating moderate volatility.

Calliditas Therapeutics AB (publ) trades at a P/E ratio of -21.52, slightly below the S&P 500 average, with a price-to-sales ratio of 16.63 and a price-to-book ratio of 29.97 reflecting a rich premium to book value. The P/FCF stands at -44.86, also below market averages. Compared to sector medians, Calliditas Therapeutics AB (publ) P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.